Results 231 to 240 of about 10,879 (246)

Advantages of edaravone dextrosanol in elderly patients with acute cerebral infarction versus edaravone: a preliminary study

International Journal of Neuroscience
To analyze and compare the application advantages of Edaravone and Edaravone Dextrosanol in elderly patients with acute cerebral infarction (ACI).A retrospective analysis of clinical data from 113 elderly AIS patients admitted to our hospital between January 2022 and January 2023 was conducted.
Xiaofeng, Zhu, Qiang, Jin, Xiaojing, Liu
openaire   +2 more sources

A comparative study of the neuroprotective effects of dl-3-n-butylphthalide and edaravone dexborneol on cerebral ischemic stroke rats.

European Journal of Pharmacology, 2023
Hui Zhang, Laifa Wang, Bi Zhu, Yongping Yang, Chuan-Zhong Cai, Xueqin Wang, L. Deng, Binsheng He, Yanhui Cui, Wenhu Zhou   +9 more
semanticscholar   +1 more source

Edaravone Dexborneol Alleviates Neuroinflammation by Reducing Neuroglial Cell Proliferation and Suppresses Neuronal Apoptosis/Autophagy in Vascular Dementia Rats

Neurochemical Research, 2023
Jiawei Zhang, Yining Xiao, Hongna Liu, Lili Xu, Xing Guo, Ya Gao, Meixi Li, Jing Xu, Qianqian Qi, Peiyuan Lv   +9 more
semanticscholar   +1 more source

Ultrasound–enhanced brain delivery of edaravone provides additive amelioration on disease progression in an ALS mouse model

Brain Stimulation, 2023
Yuanyuan Shen, Ji Zhang, Yiluo Xu, Shuneng Sun, Kaili Chen, Siping Chen, Xifei Yang, Xin Chen   +7 more
semanticscholar   +1 more source

Ocrelizumab, edaravone, and valbenazine

Journal of the American Pharmacists Association, 2017
Daniel A. Hussar, Terra L. Hussar
openaire   +3 more sources

Edaravone Confers Neuroprotective, Anti-inflammatory, and Antioxidant Effects on the Fetal Brain of a Placental-ischemia Mouse Model

Journal of Neuroimmune Pharmacology, 2023
Marwa N. Atallah, T. Yamashita, Xiao Hu, Xinran Hu, Koji Abe   +4 more
semanticscholar   +1 more source

FDA approves edaravone for amyotrophic lateral sclerosis

American Journal of Health-System Pharmacy, 2017
FDA on May 5 announced the approval of edaravone injection for the treatment of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. ALS is a rapidly progressive, degenerative neurologic disorder that affects the control of motor neurons and results in the atrophy of muscles,
openaire   +3 more sources

Edaravone Maintains AQP4 Polarity Via OS/MMP9/β-DG Pathway in an Experimental Intracerebral Hemorrhage Mouse Model.

Molecular Neurobiology
Zhenhua Wang, Yuan Li, Zhixu Wang, Yuhui Liao, Qingqing Ye, Shilong Tang, Ting Wei, Pengyu Xiao, Juan Huang, Weitian Lu   +9 more
semanticscholar   +1 more source

Edaravone Attenuates Aβ 1-42-Induced Inflammatory Damage and Ferroptosis in HT22 Cells

Neurochemical Research, 2022
Shenglong Guo, Q. Lei, Hena Guo, Qiang Yang, Y. Xue, Ruili Chen   +5 more
semanticscholar   +1 more source

Edaravone: a new treatment for ALS on the horizon?

The Lancet Neurology, 2017
Orla Hardiman, Leonard H. van den Berg
openaire   +3 more sources